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Abstract
Parenteral and oral routes have been the traditional methods of administering cytotoxic agents to 
cancer patients. Unfortunately, the maximum potential effect of these cytotoxic agents has been 
limited because of systemic toxicity and poor tumor perfusion. In an attempt to improve the 
efficacy of cytotoxic agents while mitigating their side effects, we have developed modalities for 
the localized iontophoretic delivery of cytotoxic agents. These iontophoretic devices were 
designed to be implanted proximal to the tumor with external control of power and drug flow. 
Three distinct orthotopic mouse models of cancer and a canine model were evaluated for device 
efficacy and toxicity. Orthotopic patient-derived pancreatic cancer xenografts treated biweekly 
with gemcitabine via the device for 7 weeks experienced a mean log2 fold change in tumor 
volume of −0.8 compared to a mean log2 fold change in tumor volume of 1.1 for intravenous (IV) 
gemcitabine, 3.0 for IV saline, and 2.6 for device saline groups. The weekly coadministration of 
systemic cisplatin therapy and transdermal device cisplatin therapy significantly increased tumor 
growth inhibition and doubled the survival in two aggressive orthotopic models of breast cancer. 
The addition of radiotherapy to this treatment further extended survival. Device delivery of 
gemcitabine in dogs resulted in more than 7-fold difference in local drug concentrations and 25-
fold lower systemic drug levels than the IV treatment. Overall, these devices have potential 
paradigm shifting implications for the treatment of pancreatic, breast, and other solid tumors.
INTRODUCTION
Chemotherapy has had an immeasurable impact on the field of oncology since its inception 
in the 1940s (1). Cytotoxic and molecularly targeted agents have become a mainstay of 
cancer therapy and play a large role in curative resection and high-risk operations of solid 
tumors. Tumors at high risk of recurrence or that may involve close margins at the time of 
operation such as head and neck, rectal, gastroesophageal, advanced gastric, and pancreatic 
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cancers, and soft tissue sarcomas benefit from neoadjuvant chemotherapy and/or radiation 
(2–7). However, dense stromal environments and poor vascularization impede drug 
diffusion, reducing exposure to the primary tumor (8–11). This impaired drug delivery has 
contributed to the recurrence in and overall dreadful prognosis of certain solid tumors (9, 
11). To improve local control at the primary tumor, new drug delivery strategies are 
necessary to effectively concentrate the active drug in the tumor site.
Local drug delivery technologies offer a promising adjunct to systemic delivery. They exist 
in a variety of form factors designed to facilitate the delivery of drug directly to the site of 
disease in a controlled manner. Many of these are biodegradable polymeric depots designed 
to maintain therapeutic concentrations of drug at the tumor site for a prolonged period. 
However, only a small number of these technologies have demonstrated potentially curative 
preclinical results for cancer applications, and far fewer have progressed toward clinical 
practice. A key challenge of many of these local drug delivery systems, particularly 
polymeric drug–eluting technologies like the Gliadel wafer, has been diffusion limitations 
(12, 13). The lack of spatial distribution of drugs and elevated interstitial fluid pressures in 
solid tumors have relegated the use of many local drug delivery systems to postsurgical 
therapy (12).
A subset of local drug delivery devices involves the use of electric fields to drive drugs into 
tissues, using a technique known as iontophoresis. Iontophoretic devices are capable of 
overcoming diffusion barriers by electromigratory and electroosmotic forces (14, 15). 
Advances in ophthalmologic and urologic devices have enabled the effective iontophoretic 
and electroosmotic delivery of mitomycin C and dexamethasone to tissues while reducing 
the systemic effects of these drugs (16, 17). Here, we developed and investigated a new 
iontophoretic device platform for the local delivery of cytotoxic therapies to solid tumors. 
These iontophoretic devices were designed to be implanted proximal to the tumor with 
external user control of power and drug flow.
To evaluate the broad application of iontophoretic devices as potential anticancer therapies, 
we elected to test the devices in a diverse set of orthotopic mouse models of cancer, 
including pancreatic and breast cancer models, and a canine model for pharmacokinetic 
(PK) studies (18–21). These cancer types were chosen as models because of their major 
local control issues—nearly 40% of patients with locally advanced, nonmetastatic pancreatic 
cancer do not have the opportunity to undergo surgery because of tumor invasion into 
adjacent vessels, and inflammatory breast cancers have significant chest wall involvement, 
where extensive surgery may be needed (22, 23). We describe an in-depth preclinical 
characterization of iontophoretic delivery of cytotoxic agents. We report that these devices 
deliver high levels of cytotoxic drugs to the tumor, reduce systemic exposure of the drugs, 
and potently prevent tumor growth. Iontophoretic devices offer entirely new modalities for 
the treatment of cancer by improving local tumor control and organ preservation.
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RESULTS
Design and fabrication of the devices
Our devices were designed to adapt conventional iontophoretic drug delivery techniques 
(Fig. 1, A and B). The devices could be either implanted, such as in the case of pancreatic 
tumors, or used transdermally, for breast tumors, and primarily consisted of an electrode in 
direct contact with the drug solution, a polyurethane or polydimethylsiloxane (PDMS) 
reservoir surrounding the electrode, and an inlet and outlet for drug flow-through where the 
solution in contact with the biological tissue was continuously replaced and replenished 
(Fig. 1C). This continuous flow design maintained a constant drug concentration around the 
electrode and pressure within the device. Under an applied electric potential, the drug was 
transported in the direction normal to the electrode and into the tissue. Initially, we 
fabricated our devices using silver because it is the most efficient material for drug transport 
into tissue surrogates (15). However, the electrochemical reaction at the silver anode 
interface prohibited its long-term use owing to the buildup of silver chloride and depletion 
of silver. Platinum was chosen for long-term implanted device studies, whereas silver was 
used for nonimplanted device studies.
Iontophoretic drug delivery optimization in tumors and in human skin
Several device parameters were evaluated to determine the optimal drug transport 
conditions, including drug concentration (Fig. 1D) and applied current (Fig. 1E). To test 
these parameters, we implanted the device into an orthotopic patient-derived xenograft 
(PDX) model of pancreatic cancer. The mice were allowed to recover for 1 week after 
device implantation, to allow wound healing and encapsulation. A single treatment of 
gemcitabine was administered, and tumors and plasma were harvested directly thereafter. 
Drug transport into PDX tumors with a constant current of 2 mA for 10 min was highest for 
40 versus 20 and 10 mg/ml gemcitabine (Fig. 1D and fig. S1). There was a significantly 
higher concentration of gemcitabine in plasma as well (Fig. 1D). Furthermore, the 
application of 2 mA of constant current for 10 min using 40 mg/ml gemcitabine resulted in 
1.3-fold greater drug transport compared to 1 mA. Plasma levels of gemcitabine were 
significantly greater for 2 mA compared to 1 mA (Fig. 1E). The most beneficial drug 
concentration is one that has highest uptake in the tumor with low plasma levels, thus 20 
mg/ml gemcitabine at 2 mA was used in PK and efficacy studies.
Ex vivo drug transport studies were conducted using pancreatic cancer PDX tumors and 
human skin. To test the transport of gemcitabine in the ex vivo PDX tumors, we sutured the 
devices onto the tumors and placed the counter electrode on the contralateral side of the 
tumor. A current of 2 or 0 mA was applied for 10 min, and the tumors were subsequently 
analyzed. The application of 2 mA constant current resulted in an 8.9-fold increase in drug 
transport compared to the passive diffusion control (0 mA) into the tumor (Fig. 1E). The pH 
of the gemcitabine solution was measured before and after device treatment, and the 
treatment reduced the pH of the solution by 1.3 units, indicating a more acidic environment 
that may have assisted in gemcitabine transport.
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The transport of cisplatin into ~1-mm-thick human skin ex vivo was evaluated. A current of 
1 or 0 mA was applied for 25 min, and the skin and solution were snap-frozen, processed, 
and analyzed by inductively coupled plasma mass spectrometry (ICP-MS). The application 
of 1 mA constant current resulted in an 11.4-fold increase in platinum transported into the 
human skin compared to passive diffusion (Fig. 1E). Murine skin was evaluated using the 
same method, revealing similar drug transport into the skin with current but larger transport 
through the skin (fig. S2). There was a minor drop in pH (~0.2 pH units) for the cisplatin 
solution after device treatment.
PK and biodistribution of cytotoxic drugs in mice
Iontophoretic delivery of gemcitabine was further characterized with respect to PK in an 
orthotopic PDX model of pancreatic cancer (18, 19). Recent reports in lung, pancreatic, 
breast, and colon cancers, as well as glioblastoma, suggest that patient tumors directly 
implanted in immunocompromised mice exhibit response rates to cytotoxic or targeted 
therapies more similar to patient responses (24–27). In the PDX model, devices were 
surgically implanted when the tumor reached a median size of 260 mm3. One week after 
device implantation, a single treatment was administered, and tumors were harvested at 
designated time points. We performed a PK study comparing device delivery of gemcitabine 
to intravenous (IV) delivery (80 mg/kg) (Fig. 2). Gemcitabine IV dosing at 80 mg/kg was 
chosen because in mice it more appropriately matches the gemcitabine PK profile in humans 
than the maximum tolerated dose of 120 mg/kg (28–30).
Gemcitabine plasma exposure as measured by the area under the curve (AUC) for IV 
delivery was 52.0 hour*μg/ml, with no detectable gemcitabine in the plasma of the animals 
receiving gemcitabine via iontophoretic device. Gemcitabine tumor AUC for iontophoretic 
delivery was an order of magnitude greater than IV delivery (344.4 versus 30.8 hour*μg/g, 
respectively) (Fig. 2). The average penetration distances that gemcitabine was detected in 
the tumors in the direction away from the devices were 4.7 mm at 0 hours and 3 mm at 3 and 
6 hours; for IV gemcitabine–treated mice, gemcitabine was detected throughout the entire 
tumor, but at lower drug concentrations. The pancreas had a better blood supply than the 
tumor, which resulted in greater gemcitabine exposure after IV compared to device delivery. 
Drug accumulation in the pancreatic tumor and distance of drug transport were dependent on 
the inflow gemcitabine concentration, which correlated with the in vitro drug transport 
results (fig. S3).
Device delivery of cisplatin in an orthotopic SUM149 xenograft model of human breast 
cancer was compared with IV delivery of cisplatin (Fig. 2). Concurrent device and IV 
delivery of cisplatin was added as an arm of the study based on the low systemic exposure of 
cisplatin from device treatments (plasma exposure was 2.0 hour*μg/ml). A single treatment 
was administered after adhesion of the device to the skin above the tumor. Platinum plasma 
exposures as measured by area under the concentration versus time curve for device 
delivery, IV (5 mg/kg), and device + IV (5 mg/kg) delivery were comparable at 2.0, 9.9, and 
10.7 hour*μg/ml, respectively. However, tumor AUC for device + IV delivery was nearly 
twofold greater than that for IV delivery alone (83.4 versus 42.4 hour*μg/g, respectively) 
(Fig. 2).
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In PK studies in mice, device delivery resulted in lower kidney, left inguinal lymph node, 
and right inguinal mammary exposure to cisplatin (1 mg/ml) but more skin exposure 
compared with IV delivery (fig. S4). The combination of device + IV delivery resulted in the 
largest cisplatin exposure to all organs.
Device delivery of gemcitabine reduces tumor volume and cancer cell proliferation 
compared with IV delivery
To evaluate the antitumor activity of gemcitabine and cisplatin delivered by the 
iontophoretic devices, we performed efficacy studies in orthotopic pancreatic and breast 
cancer models. In the pancreatic cancer model, devices were surgically implanted onto 
orthotopic human pancreatic tumors when their size reached a median size of 260 mm3. 
Mice were treated twice per week for up to 7 weeks with device gemcitabine (20 mg/ml), 
device saline (0.9% NaCl), IV gemcitabine (80 mg/kg), or IV saline. Implanted devices 
impaired ultrasound imaging, and thus, tumor volumes were measured only after completion 
of the treatment.
Device gemcitabine resulted in significant tumor regression in seven of seven mice, 
outperforming IV gemcitabine and the control arms of IV and device saline over the 7-week 
period of the study (Fig. 3A). Mice treated with device gemcitabine had a mean log2 fold 
change in tumor volume of −0.8 compared to a mean log2 fold change in tumor volume of 
1.1 for IV gemcitabine, 3.0 for IV saline, and 2.6 for device saline groups. Mice treated with 
device saline had tumor volumes that were not statistically different from those of mice 
treated with IV saline. Device gemcitabine was better tolerated on the basis of greater body 
weight gain compared to IV gemcitabine (fig. S5), but no statistical difference in alanine 
transaminase, aspartate transaminase, blood urea nitrogen (BUN), and lipase was noted for 
the different delivery routes (fig. S6). Histological samples from the tumors after 7 weeks of 
treatment revealed a significant decrease in Ki-67, a marker of cell proliferation, in mice 
treated with gemcitabine from the iontophoretic device compared with tumors from mice 
that received IV gemcitabine (Fig. 3B).
Device delivery of cisplatin combined with radiotherapy prolongs survival of mice with 
human breast cancer
This iontophoretic delivery technology was further evaluated in orthotopic breast cancer 
models: SUM149 human xenograft and T11 syngeneic. In both models, we compared the 
efficacy of device cisplatin, IV cisplatin (5 mg/kg), device + IV cisplatin (5 mg/kg), device 
saline, and IV saline (Fig. 4A). Once the human xenograft breast tumors reached ~50 mm3, 
the mice were treated every week for a total of four doses. The skin of mice after four 
device-based treatments showed no scarring or deformation (Fig. 4B). Mice bearing T11 
tumors received two doses of the same test arms 1 week apart beginning 5 days after 
inoculation (~20 mm3). The number of treatments varied across different tumor models 
owing to differences in tolerability of treatments.
Both device cisplatin and IV cisplatin resulted in significant tumor growth inhibition 
compared to controls in the SUM149 and T11 models (Fig. 4C). Device + IV cisplatin, 
however, outperformed device cisplatin and IV cisplatin in both tumor models. Device 
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cisplatin, IV cisplatin, and device + IV cisplatin extended the life span from a median of 49 
days without treatment to 60, 68, and >100 days, respectively, in the SUM149 model. 
Device cisplatin, IV cisplatin, and device + IV cisplatin extended the life span from a 
median of 10 days without treatment to 20, 22, and 32 days, respectively, in the T11 model 
(Fig. 4C).
Device cisplatin was better tolerated compared to IV cisplatin and device + IV cisplatin as 
shown by the staining of kidneys for a molecular marker of DNA damage and repair, 
γH2AX, and platinum-DNA adducts (fig. S7). In addition, histological samples from tumors 
revealed almost equivalent γH2AX staining after treatment with device cisplatin and IV 
cisplatin and significantly greater γH2AX staining in device + IV cisplatin–treated mice 
(Fig. 4D).
We next determined whether the addition of radiotherapy to the device delivery of cisplatin 
could improve the chemotherapeutic effect of device + IV cisplatin. Mice bearing orthotopic 
T11 tumors received a single dose of radiation (10 Gy); device cisplatin; device cisplatin + 
radiation (10 Gy); IV cisplatin (5 mg/kg); IV cisplatin (5 mg/kg) + radiation (10 Gy); device 
+ IV cisplatin (5 mg/kg); or device cisplatin + IV cisplatin (5 mg/kg) + radiation (10 Gy) 5 
days after tumor inoculation (~20 mm3). There were three major cohorts of response (Fig. 
4E). Mice treated with a single dose of radiation, device cisplatin, or IV cisplatin showed 
similar tumor growth rates and survival (~17 days), which were significantly improved 
compared with control animals that did not receive treatment. Mice treated with a single 
dose of combination therapy—device cisplatin + radiation, IV cisplatin + radiation, or 
device + IV cisplatin—also showed similar tumor growth rates and survival (~23 days).
Device + IV cisplatin + radiation outperformed all other treatment groups in tumor growth 
inhibition and survival (~26 days) (P < 0.0002, log-rank test). Tumor growth inhibition in 
the device + IV + radiation group was not significant compared to the other groups [P = 
0.084, analysis of variance (ANOVA)]. The discrepancy between the mice treated with 
radiation and without radiation is a result of the treatment schedule. In the nonradiation T11 
study, we treated the mice twice to establish a difference in effect. For the radiation T11 
study, we treated the mice only once because of the radiation dose administered. Overall, the 
addition of radiation significantly improved survival in the T11 breast tumor mouse model 
compared with the other device cisplatin groups (P < 0.0001, log-rank test).
PK of iontophoretic delivery in dogs
To further evaluate the implantable iontophoretic device, we used a non–tumor-bearing dog 
model. A laparotomy was performed to expose the pancreas, and a device (Fig. 5A) was 
sutured directly onto the pancreas. A constant current of 10 mA was applied for 60 min 
using either 40 or 10 mg/ml gemcitabine. For the IV treatment arm, the human dose of 1 
g/m2 was administered for 30 min.
There was no drug detected in the plasma of the animals when a low gemcitabine 
concentration (10 mg/ml) was used in the device treatment (Fig. 5B). In the plasma of dogs 
treated with the high gemcitabine concentration (40 mg/ml) delivered by the device, two of 
five dogs had detectable levels of gemcitabine, but the levels of gemcitabine detected were 
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more than 25-fold lower than the IV treatment. There was a higher concentration of 
gemcitabine in the pancreas after device delivery of 40 mg/ml gemcitabine versus IV and 10 
mg/ml gemcitabine (Fig. 5C). The distances of gemcitabine transport after device treatment 
using high and low gemcitabine concentrations were statistically different at 9.6 and 6.3 mm 
away from the electrode, respectively (Fig. 5D).
DISCUSSION
Local delivery of chemotherapies could have a revolutionary impact on the treatment of 
cancer by maximizing the effect at the target site and sparing off-target tissue toxicities (11). 
Yet, the translation of the local drug delivery technologies from basic research into everyday 
cancer treatments has remained elusive. We decided to take an iontophoretic approach to 
improve local delivery and drug penetration into the tumor. Iontophoresis is capable of 
overcoming considerable flow and pressure gradients, particularly those found in solid 
tumors (16). In addition, a large number of small molecule drugs are capable of being 
delivered by iontophoresis (31–34).
Here, we show that iontophoretic devices can deliver substantial amounts of drugs to the 
tumor site of interest with limited systemic exposure in mice and in dogs. Our preclinical 
results suggest that device delivery of gemcitabine and cisplatin may potentiate the current 
treatment of solid tumors by enhancing the therapeutic index of the drugs. In addition, the 
coadministration of systemic therapy, device therapy, and radiotherapy proved feasible and 
significantly improved tumor growth inhibition and survival in breast cancer models. These 
studies showcase the versatility of iontophoresis, building on the work of Di Stasi et al. (16).
Surgery remains the optimal therapy for most solid tumors, yet only 10 to 15% of pancreatic 
cancer patients, 20% of hepatocellular carcinoma patients, 28% of non–small cell lung 
cancer patients, 45% of gastric cancer patients, and 15 to 20% of esophageal cancer patients 
undergo curative resection, because the tumor has either invaded critical vessels or 
metastasized to more distant organs (35–40). In addition, tumor resection—even when 
successful—can negatively affect quality of life owing to disfiguration or high-risk 
operations. Radiation therapy is used in combination with surgery; however, it can also have 
major side effects, including skin reactions, fatigue, poor surgical wound healing, and 
secondary malignancies (41). Our device has the potential to be an adjunct to surgery, which 
is supported by the significant tumor regression in the PDX model of pancreatic cancer 
achieved by device gemcitabine treatments. The device’s ability to increase intratumoral 
drug concentrations well above current methods of drug administration while maintaining 
low systemic exposure may increase rates of tumor regression and margin-negative surgical 
resection and thus improve long-term patient outcomes.
For patients with metastatic disease and debilitating local symptoms such as pain due to 
nerve involvement or obstruction, an iontophoretic, local delivery device could provide a 
modality for palliative care. Moreover, this therapy could be used as an adjunct treatment to 
systemically administered therapy to better treat the primary tumors while systemic 
therapies concomitantly treat metastatic disease; our data in mice revealed a reduction in 
tumor growth when the device treatment was combined with IV treatments. One tremendous 
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advantage would be to leverage our device for the delivery of agents that are limited by 
systemic toxicity. For example, FOLFIRINOX is a promising cytotoxic combination but 
with limited utility in many patients because of its high level of systemic toxicity (42). The 
combination iontophoretic delivery of two drugs (5-fluorouracil and leucovorin) from the 
FOLFIRINOX regimen in healthy pig buccal tissue has shown potential for treatment of 
head and neck cancer (34).
Although our iontophoretic devices improved local drug transport compared with IV routes, 
their efficacy may be further improved by potentially altering the dosing schedule, changing 
the electrode material, optimizing drug formulations, and configuring the device according 
to anatomy. Because of the high drug concentrations in the tumor and low level of systemic 
exposure after a single treatment, the number of device treatments could be increased. 
Because Ag/AgCl electrodes are more efficient in drug delivery and minimize pH changes 
in the drug solution, these electrodes should be investigated for human studies. Drug 
formulation plays an important role in the iontophoretic delivery of drugs through 
competing ions and electroosmotic flow, and the evaluation of formulation excipients could 
improve total drug delivered and distance of drug transport (15). Configuring these devices 
to fit the shape of the tumor and surrounding anatomy could improve efficacy by creating 
better contact between the device and tumor tissue and, in the case of pancreatic cancer, 
strategically delivering the cytotoxic agents to the area that would enable tumor resection. 
For the device treatment of breast cancer, the skin acts as a barrier reducing drug transport; 
thus, placing the device subcutaneously would increase the amount of drug delivered.
Some key parameters that need to be further understood for translation are safe and tolerated 
current densities at the device-tumor interface in humans and iontophoretic drug transport in 
human solid tumors. These data will build on the large amount of research about drug 
transport through the layers of the skin, using microneedle patches and transdermal 
iontophoretic devices (14). In a similar fashion to the scale-up of devices from our mouse to 
dog studies, the treatments will need to be scaled to address larger human tumors. 
Evaluation of toxicity in large animals, such as dogs, is a necessary step in the progression 
of the device toward clinical trials. There are several devices guiding our path forward with 
the U.S. Food and Drug Administration, including an iontophoretic Foley catheter by 
Physion EMDA, with indications for bladder cancer and Peyronie’s disease, and the 
InfusAid Pump for intrahepatic artery injection of chemotherapeutic agents, among others 
(43, 44).
Our iontophoretic device technology may be co-opted for several clinical applications, 
including as an adjunct to surgery or to systemic therapy, similar to the current practice of 
using radiation therapy in the setting of metastatic cancer. Looking beyond pancreatic and 
breast cancers, this iontophoretic approach can be applied to a variety of other cancers, 
including head and neck cancer, sarcomas, and colorectal and gastric cancers. The device 
could be extended to the delivery of a multiplicity of drugs to improve primary tumor 
resection, preserve organ function, and improve quality of life for patients. Overall, our 
devices could potentially offer entirely new modalities for the treatment of cancer under the 
emerging field of interventional oncology.
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MATERIALS AND METHODS
Study design
The aim of this study was to develop iontophoretic devices for the local treatment of solid 
tumors. It was hypothesized that iontophoretic devices could be used to deliver 
chemotherapies directly to tumors, overcoming major barriers of drug efficacy. In vitro 
work was first performed to optimize and test the iontophoretic delivery of gemcitabine and 
cisplatin into tissues. For PK and efficacy studies, mice were randomized into the 
experimental and control groups. Tumor measurements for the efficacy studies were 
performed by blinded animal handlers from the University of North Carolina (UNC) Animal 
Studies Core Facility. The study endpoint for efficacy in the mouse model of pancreatic 
cancer was an interval of 7 weeks; the study endpoint for efficacy in the mouse model of 
breast cancer was time to tumor progression to 2.0 cm in one dimension. For histological 
analysis, tumors were annotated, and the number of positively stained cells according to 
stain intensity was quantified. Finally, we tested these devices in randomized dogs to 
highlight the translatability of the technology; for these studies, power analysis involving 
Wilcoxon rank sum tests was used to obtain the sample sizes needed. No outlying data 
points were excluded in the studies.
Device fabrication
Iterative device design was performed using a three-dimensional computer-aided design 
software (SolidWorks). For the long-term implanted murine devices, a 5-mm platinum 
(Strem Chemicals) disc was soldered to a stainless steel cable wire and embedded in a 
polyurethane (Hapco Steralloy 2056) reservoir before cross-linking. A steel ring was also 
embedded in the polyurethane reservoir to act as an anchor for suturing the device onto the 
tumor. The steel wire was then threaded through the multiluminal tubing, and the tubing-
reservoir interface was encased in heat-shrink tubing. A semipermeable 14K cellulose 
membrane (Fisher Scientific) was adhered to the reservoir for enclosure. For the short-term 
murine transdermal devices, an 8.6-mm silver disc was soldered to a 36-gauge copper wire 
and embedded in a PDMS (Sylgard 184) reservoir before cross-linking. The copper wire 
was threaded through a multiluminal tube, and the tube was inserted into the reservoir for 
inflow of drug. Another multiluminal tube was inserted on the contralateral side of the 
reservoir for drug efflux. For the short-term implanted canine devices, a 1-cm silver (Fisher 
Scientific) circular disc was soldered to an insulated copper conducting wire and embedded 
in a polyethylene reservoir covered by a 14K semi-permeable cellulose membrane. A dual 
lumen tube was inserted into the reservoir for drug flow into and out of the reservoir.
Animal studies
All procedures were approved by the appropriate Institutional Animal Care and Use 
Committee before initiation. All animals used in PK, biodistribution, and efficacy studies 
were allowed to acclimate for at least 1 week to the animal facilities before experimentation. 
Animals were exposed to a 12-hour light/dark cycle and received food and water ad libitum 
through the studies. Each tissue required a different current density for functionality and 
safety of the device treatment. For quantitation of gemcitabine and cisplatin plasma 
concentrations, blood samples were collected into heparinized tubes, and plasma was 
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generated and frozen with liquid nitrogen; tissue and device were extracted and snap-frozen 
with liquid nitrogen and stored at −80°C. Total gemcitabine was extracted from frozen 
plasma and organs with a protein precipitation method and analyzed by ultraviolet–high-
performance liquid chromatography (UV-HPLC) (45). Total platinum was extracted using a 
nitric acid degradation method and analyzed by ICP-MS (46).
Ex vivo studies
Pancreatic cancer PDXs—De-identified tumors of pancreatic cancer patients were 
grafted and passaged in athymic nude mice as described previously (18, 19). Upon reaching 
~200 mm3, the tumors were directly removed and placed into petri dishes with 2 ml of 
saline. Devices were sutured directly onto the tumor using 6-0 nylon, followed by either no 
current (control) or 2 mA of current (current density, 4 mA/cm2) for 10 min with a drug 
flow of 50 μl/min into the device. After treatment, the tumors were snap-frozen and 
sectioned using a cryostat microtome. The sections were analyzed by UV-HPLC.
Human skin—De-identified human skin was provided by the cooperative human tissue 
network. The frozen skin was thawed and sectioned into 2 cm × 2 cm squares before drug 
transport studies. The transport of cisplatin in skin was evaluated using a modified Franz 
diffusion cell with the device directly above the skin. The receptor chamber was filled with 
5 ml of saline. No current or 1 mA of current (current density, 0.5 mA/cm2) was applied for 
25 min, and the skin and solution were snap-frozen, processed, and analyzed by ICP-MS.
PK studies
PKs were evaluated in pancreatic cancer PDXs in mice, SUM149 orthotopic xenografts in 
mice, and in healthy dogs, as described in Supplementary Methods.
Efficacy studies
Pancreatic cancer PDXs—The technical protocols for surgical implantation of the 
device and device treatments were identical to the PK studies. Mice were treated biweekly 
for 7 weeks using device gemcitabine (20 mg/ml), device saline (0.9% NaCl), IV saline, or 
IV gemcitabine (80 mg/kg).
SUM149 orthotopic xenograft and T11 orthotopic syngeneic models—The 
technical protocol for device treatments was identical to the PK studies. Mice were treated 
two or four times per week using device cisplatin, IV cisplatin (5 mg/kg), device + IV (5 
mg/kg) cisplatin, device saline (0.9% NaCl), or IV saline. Tumors derived from BALB/c 
TP53−/−orthotopic mammary gland transplant line (T11) were passage in BALB/c wild-type 
mice by subcutaneous injection of 500,000 cells re-suspended in Matrigel (50:50) into the 
left inguinal mammary gland. The day before the scheduled treatment, the mice were shorn 
with clippers, and the residual hair was removed using Nair. For the radiation studies, at 2 
hours after injection, the tumors were subjected to radiation of 10 Gy with XRAD 320. Mice 
were shielded with a lead shield to reduce irradiation of other organs.
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PK and statistical analyses
Data are expressed as means ± SD. Graphs were created with GraphPad Prism software. All 
analyses were done using SAS v9.3. PK parameters were assessed with Phoenix WinNonLin 
(version 6.0). ANOVA methods were used for comparisons of continuous values between 
groups. Unpaired t tests were used when an overall difference was detected. Unadjusted P 
values were reported for pairwise comparisons when an overall difference was detected. For 
the breast cancer efficacy studies, comparisons were made between groups at two time 
points: (i) when all mice were still alive (days 28, 9, and 9) and (ii) when all mice on 
treatment were still alive (days 42, 16, and 15). For survival data, the Kaplan-Meier method 
and log-rank tests were used for comparisons between groups. To compare the distribution 
in absolute mass of gemcitabine per mass of tissue and distance of transport between 
different pairs of methods, Wilcoxon rank sum tests were used and exact nominal P values 
were reported.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors
(A) Front and side images of the implantable and transdermal devices. (B) Device 
components and assemblies. (C) Device treatment setups in the pancreatic (implanted 
device) and breast (transdermal device) cancer models where the drug is supplied to the 
device, using a syringe pump and electrical current via a DC power supply. Positive and 
negative leads connect to the device and counter electrode, respectively. (D) Device 
parameters of drug concentration (at constant current and time) and applied current (at 
constant concentration and time) were evaluated in mice with patient-derived pancreatic 
cancer xenografts. Data are means ± SD (n = 5). P values were determined by one-way 
ANOVA with unpaired t test. (E) Role of current on drug transport in ex vivo tumor and 
human skin tissue. Gemcitabine transport through PDX tumor tissue was evaluated by 
applying a current of 2 or 0 mA for 10 min and comparing drug transport into tumor. Data 
are means ± SD (n = 6). Cisplatin transport into human skin was evaluated by applying a 
current of 1 or 0 mA for 25 min and comparing drug transport into and through the skin. 
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Data are means ± SD (n = 5). P values were determined by unpaired t test. NS, not 
significant.
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Fig. 2. PK of gemcitabine and cisplatin delivered by iontophoretic devices in mouse models of 
human pancreatic and breast cancers
Iontophoretic device delivery was compared with IV delivery. PK of gemcitabine (20 
mg/ml) delivered by device compared to IV was evaluated in an orthotopic PDX model of 
pancreatic cancer. Mice were administered a single treatment of gemcitabine through the 
device. Organs were collected from each animal at various times, and total gemcitabine 
concentrations were analyzed. Data are means ± SD (n = 3 to 5 animals per group). The 
limit of gemcitabine quantitation was 1 μg/ml. P values were determined by unpaired t test. 
PK of cisplatin delivered by device compared to IV and device + IV was evaluated in 
SUM149 orthotopic xenografts of breast cancer. Mice were administered a single treatment 
of cisplatin. Organs were collected from each animal at various times, and total platinum 
concentrations were analyzed. Data are means ± SD (n = 5 animals per group). The limit of 
platinum quantitation was 5 ng/ml. P values were determined by one-way ANOVA with 
unpaired t test comparing device cisplatin and device + IV cisplatin.
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Fig. 3. Therapeutic effect of gemcitabine delivered iontophoretically in a pancreatic cancer PDX 
model
(A) Efficacy of device gemcitabine, IV gemcitabine, device saline, and IV saline in PDX 
mice treated twice per week for 7 weeks. Data are fold change in tumor volume (log2) (n = 7 
for IV and device gemcitabine, n = 5 to 6 for IV and device saline). (B) Histological staining 
of representative tumors in (A) for Ki-67. Ki-67 staining was quantified according to H-
score. P values were determined by one-way ANOVA with unpaired t test.
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Fig. 4. Therapeutic effect of cisplatin delivered iontophoretically in mouse tumor xenograft and 
syngeneic models of breast cancer
(A) Treatment schedule according to mouse model. (B) Efficacy and survival of animals 
treated with device cisplatin, IV cisplatin (5 mg/kg), device + IV cisplatin (5 mg/kg), device 
saline, and IV saline. SUM149 tumor xenografts were treated once per week for a total of 
four doses (n = 8 to 9 per treatment group). T11 syngeneic tumors were treated once per 
week for a total of two doses (n = 9 per treatment group). The study endpoint was time to 
tumor progression to 2.0 cm in one dimension. Volume data are means ± SD. (C) 
Representative images of murine skin before and after 4 weeks of transdermal device 
Byrne et al. Page 20
Sci Transl Med. Author manuscript; available in PMC 2016 February 04.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
treatment. (D) γH2AX staining of tumors harvested from SUM149 xenografts 24 hours after 
a single treatment. γH2AX staining was quantified according to H-score. P values were 
determined by one-way ANOVA with unpaired t test. (E) Efficacy and survival of animals 
with T11 syngeneic tumors after a single treatment of radiation (dose), device cisplatin, 
device cisplatin + radiation, IV cisplatin (dose), IV cisplatin (dose) + radiation, device + IV 
cisplatin, or device + IV cisplatin + radiation. Data are mean tumor volumes ± SEM (n = 8 
per treatment group). P values for tumor growth inhibition were determined by one-way 
ANOVA with unpaired t test; P values for survival determined by log-rank test.
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Fig. 5. Evaluation of single device treatments in dogs
(A) Device to be implanted directly onto the canine pancreas. (B) Plasma PK of gemcitabine 
during the single device (10 or 40 mg/ml) or IV (1 g/m2) treatment. (C) Organs were 
removed 1 hour after the initiation of treatment, and gemcitabine content was quantified in 
the pancreas of dogs after the administration of a single treatment. (D) Distance of 
gemcitabine transport away from the device and into the pancreatic tissue. Data are means ± 
SD (n = 5). P values were determined by Wilcoxon rank sum tests.
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